This is the most accurate, minus great news from Prurisol in FDA 2, that I think anyone has written. Thanks to aka Waverunner1.
I think that there is a possibility after the Kevetrin FDA 1, is formed that we could here about special grant, charity or agency financing for Retinoblastoma.
The speculation that early 2016, could see a speculative run up in the stock, I think is bang on. ER
|Waverunner1||Sunday, 08/23/15 03:23:16 AM|
|Post # of 120119|
I think you see a collaboration deal mid Phase 3 for Brilacidin, after preliminary B-OM results are in (June/July timeframe). Leo has already told us they won't be able to accurately value B until OM is run and they find out if it works on inflammatory conditions. Even without B-OM success I think you could see a deal at that time in the range of $500M upfront, $1B in milestones (based on NDA filing and approval) and 50% royalties. That would be using Dapto sales history (and the Merck deal) as a rough template. That probably equates to something around 5x the current stock price, at least. If OM is a raging success then any potential deal would be quite a bit more lucrative. Don't forget that with uplisting probable by the end of the year, or certainly by end of Q1 2016, you will see them added to several Russell indices next June as well (2000, 3000, and Global). The other big potential catalyst in that timeframe will be the Kevetrin Phase 2 for AML which will be well underway by that time. Next summer could prove a very exciting time for the company. Of course the market will anticipate much of that well in advance.
Disclosure: I am/we are long 10,000 PLUS SHARES.